Hi ho silver: Sun Silver’s looking to carve out its place on the ASX with a 292Moz silver equivalent resource
Silver-focused Sun Silver is looking to raise up to $13m through an IPO priced at 20c per share Its Maverick Springs project in Nevada already [more…]
Long Shortz with Frontier Energy: Flicking on Waroona’s financing switch
Stockhead’s Sarah Hughan sits down with Frontier Energy (ASX:FHE) CEO Adam Kiley to get the short end of the long story on the company’s latest [more…]
Reporting Rodeo Pt. 2: Here’s how analysts think another 7 mid-tier ASX miners performed in the March quarter
Want to know how March quarter reporting season could unfold BEFORE the reports come out? Look no further. Yesterday we gave you a look at [more…]
High Voltage: Aussie government throws graphite and HPA projects a tasty bone or two
Alpha HPA and Renascor Graphite receive a big sugar daddy hug from Albo this week Lithium news: the “spot” pricing is trending… steadily right now. [more…]
Which ASX companies are resurrecting abandoned drugs? Part 3
Several ASX companies are repurposing or resurrecting abandoned or under utilised drugs Paradigm Biopharmaceuticals identified the potential of FDA-approved PPS that has a long track [more…]
Weed Week: A VAST majority of Americans now want marijuana to be legal
Where are we in terms of US legalisation of cannabis? What about the current legal landscape for cannabis in Australia? We look at the best [more…]
There’s a graphene called ‘goldene’ and it could enable gold semiconductors to make green hydrogen
Researchers in Sweden have cracked the code to making goldene, which is just like graphene, except it’s made from gold – and it has the [more…]
Aussie capital city listings down 8.5pc on last year: PropTrack
Less homes, more buyers is the grim takeout from PropTrack’s latest analysis of property listings from around the country. New homes for sale on the [more…]
Rise and Shine: Everything you need to know before the ASX opens
Good morning everyone, and welcome to 18 April, 2024 – an important date in the history of everything, for a variety of rapidly-cobbled together [more…]
Neurotech’s Phase 2/3 autism trial meets primary endpoint
Neurotech Phase 2/3 NTIASD trial in autism spectrum disorder meets primary endpoint Study showed a statistically significant improvement in severity of illness in paediatric patients [more…]
